Skip to main content
. Author manuscript; available in PMC: 2022 May 5.
Published in final edited form as: Hypertension. 2021 Mar 15;77(5):1581–1590. doi: 10.1161/HYPERTENSIONAHA.120.16759

Figure 6. Direct exposure of aorta rings with the tumor necrosis factorα (TNFα) inhibitor C87 prevents Doxorubicin (DOXO)-mediated aortic stiffening.

Figure 6.

Direct exposure of aorta rings with vehicle (DMEM + 10% fetal calf serum + 1% Penicillin-Streptomycin); vehicle + C87 (20 μM); DOXO (1 μM DOXO); and DOXO + C87. n = 10/condition. Data are the mean ± SEM expressed as fold-change relative to vehicle. *P < 0.05 vs. vehicle; †P < 0.05 vs. DOXO.